Company intelligence / Profile preview

Bluejay Therapeutics

San Mateo/Redwood City, California, United Statesbluejaytx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Brelovitug (BJT-778) achieved 100% virologic response across all dose arms and up to 78% combined virologic response and ALT normalization as a monotherapy in Phase 2 trials for CHD. The drug received FDA Breakthrough Therapy designation in January 2025 and has PRIME and Orphan designations from the European Medicines Agency. The first patient was dosed in the AZURE-1 global pivotal clinical trial in March 2025.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Monoclonal antibodies (mAbs)TLR9 agonistHBV transcript inhibitor
Industry: Biotech

Drug pipeline

4 assets

BJT-628

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Licensing agreement with Novartis for BJT-628

Beyond the preview

Go deeper on Bluejay Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bluejay Therapeutics.

Explore the full profile